Theravance Biopharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $9.8
- Today's High:
- $10.105
- Open Price:
- $10.05
- 52W Low:
- $9.12
- 52W High:
- $12.03
- Prev. Close:
- $10.08
- Volume:
- 375856
Company Statistics
- Market Cap.:
- $532.36 million
- Book Value:
- 5.218
- Revenue TTM:
- $51.27 million
- Operating Margin TTM:
- -135.4%
- Gross Profit TTM:
- $-12046000
- Profit Margin:
- 1694.18%
- Return on Assets TTM:
- -10.75%
- Return on Equity TTM:
- -781.34%
Company Profile
Theravance Biopharma Inc had its IPO on 2014-05-16 under the ticker symbol TBPH.
The company operates in the Healthcare sector and Biotechnology industry. Theravance Biopharma Inc has a staff strength of 111 employees.
Stock update
Shares of Theravance Biopharma Inc opened at $10.05 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $9.8 - $10.11, and closed at $9.83.
This is a -2.48% slip from the previous day's closing price.
A total volume of 375,856 shares were traded at the close of the day’s session.
In the last one week, shares of Theravance Biopharma Inc have increased by +0.2%.
Theravance Biopharma Inc's Key Ratios
Theravance Biopharma Inc has a market cap of $532.36 million, indicating a price to book ratio of 1.5714 and a price to sales ratio of 14.1142.
In the last 12-months Theravance Biopharma Inc’s revenue was $51.27 million with a gross profit of $-12046000 and an EBITDA of $-68214000. The EBITDA ratio measures Theravance Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Theravance Biopharma Inc’s operating margin was -135.4% while its return on assets stood at -10.75% with a return of equity of -781.34%.
In Q2, Theravance Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 24.4%.
Theravance Biopharma Inc’s PE and PEG Ratio
- Forward PE
- 7.1839
- Trailing PE
- 0
- PEG
- -0.05
Its diluted EPS in the last 12-months stands at $-1.1 per share while it has a forward price to earnings multiple of 7.1839 and a PEG multiple of -0.05. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Theravance Biopharma Inc’s profitability.
Theravance Biopharma Inc stock is trading at a EV to sales ratio of 6.2044 and a EV to EBITDA ratio of -18.6395. Its price to sales ratio in the trailing 12-months stood at 14.1142.
Theravance Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $446.63 million
- Total Liabilities
- $24.55 million
- Operating Cash Flow
- $11.05 million
- Capital Expenditure
- $852000
- Dividend Payout Ratio
- 0%
Theravance Biopharma Inc ended 2024 with $446.63 million in total assets and $0 in total liabilities. Its intangible assets were valued at $446.63 million while shareholder equity stood at $280.16 million.
Theravance Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $24.55 million in other current liabilities, 1000.00 in common stock, $-891644000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $-42521000.00 and cash and short-term investments were $167.45 million. The company’s total short-term debt was $9,160,000 while long-term debt stood at $0.
Theravance Biopharma Inc’s total current assets stands at $192.00 million while long-term investments were $0.00 and short-term investments were $209.97 million. Its net receivables were $15.80 million compared to accounts payable of $1.57 million and inventory worth $979000.00.
In 2024, Theravance Biopharma Inc's operating cash flow was $11.05 million while its capital expenditure stood at $852000.
Comparatively, Theravance Biopharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $9.83
- 52-Week High
- $12.03
- 52-Week Low
- $9.12
- Analyst Target Price
- $13.4
Theravance Biopharma Inc stock is currently trading at $9.83 per share. It touched a 52-week high of $12.03 and a 52-week low of $12.03. Analysts tracking the stock have a 12-month average target price of $13.4.
Its 50-day moving average was $9.81 and 200-day moving average was $10.57 The short ratio stood at 24.72 indicating a short percent outstanding of 0%.
Around 1207.4% of the company’s stock are held by insiders while 10087% are held by institutions.
Frequently Asked Questions About Theravance Biopharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.